Table 2. Description of Corticosteroid Use Stratified by Treatment Group.

Treatment group	Prolonged corticosteroid use		New anti-TNF agent use		P value
	Median (IQR)	Mean (SD)	Median (IQR)	Mean (SD)
Crohn disease
Budesonide, mg
0-12 mo Before entry	5.3 (0-9.0)	4.4 (4.3)	0	0.5 (2.0)	<.001
1-6 mo After entry	6.0 (0-9.0)	4.8 (4.2)	0	0.3 (1.7)	<.001
7-12 mo After entry	0 (0-6.0)	2.6 (3.9)	0	0.4 (1.8)	<.001
Systemic Corticosteroid, mg prednisone equivalent
0-12 mo Before entry	0 (0-24.5)	13.4 (17.9)	0 (0-9.5)	8.3 (22.4)	<.001
1-6 mo After entry	0 (0-22.3)	12.8 (18.6)	0	6.6 (45.8)	<.001
7-12 mo After entry	0	4.7 (12.2)	0	3.5 (14.2)	.06
Ulcerative colitis
Budesonide, mg
0-12 mo Before entry	0	1.2 (3.0)	0	0.3 (1.6)	<.001
1-6 mo After entry	0	1.3 (3.0)	0	0.3 (1.7)	<.001
7-12 mo After entry	0	0.6 (2.1)	0	0.4 (2.1)	.10
Systemic corticosteroid, mg prednisone equivalent
0-12 mo Before entry	25.0 (14.3-35.0)	24.8 (17.4)	0 (0-21.5)	11.3 (16.7)	<.001
1-6 mo After entry	23.3 (13.0-35.9)	25.1 (18.8)	0 (0-19.3)	10.6 (19.0)	<.001
7-12 mo After entry	0 (0-15.4)	9.0 (15.1)	0	4.2 (12.2)	<.001

Abbreviations: IQR, interquartile range; TNF, tumor necrosis factor.